Nasdaq Grants HCW Biologics Extension to Regain $1.00 Bid Price Compliance by July 29
HCWB has more than doubled off its 52-week low of $0.25 on light trading volume (0.1× avg).
Summary
HCW Biologics has secured an extension from a Nasdaq Hearings Panel to regain compliance with the $1.00 minimum bid price rule. The company must achieve a bid price of at least $1.00 for 20 consecutive trading days by July 29, 2026. This follows the delisting notice disclosed in the March 31, 2026 10-K and the proposed reverse stock split outlined in the April 17, 2026 proxy filing. While the extension provides a temporary reprieve, failure to meet the new deadline could still result in delisting. Investors should watch the upcoming shareholder vote on the reverse stock split at the June 15th Annual Meeting.
At the time of this announcement, HCWB was trading at $2.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $0.25 to $8.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.